异常受精卵可产生健康活产:改进的植入前遗传学检测技术可用于挽救体外受精周期中的可移植胚胎
该纵向队列研究纳入2015年1月至2016年9月共556名女性的719个植入前非整倍体遗传学检测(PGT-A)周期,对单原核(1PN)或三原核(2.1PN)来源的囊胚进行倍性评估。1PN来源囊胚多数为二倍体(9/13,69.2%),2.1PN来源囊胚多数为二倍体(12/14,85.7%);共获得8枚额外的平衡二倍体可移植胚胎,并实现3例活产。作者认为整合可靠倍性评估的增强PGT-A技术可有效挽救异常受精卵来源的囊胚用于临床。
要点
- 1PN来源囊胚69.2%(9/13)为二倍体,2.1PN来源囊胚85.7%(12/14)为二倍体。
- 26个PGT-A周期(3.6%,26/719)获得至少一枚异常受精卵来源囊胚。
- 共获得8枚额外平衡二倍体可移植胚胎,3例活产(1例来自1PN,2例来自2.1PN)。
核心结论
- 整合可靠倍性评估的增强PGT-A技术可有效挽救异常受精卵来源的囊胚用于临床。
研究设计与样本
- 纵向队列研究,2015年1月至2016年9月,涉及556名女性的719个PGT-A周期,在获得单原核(1PN)或三原核(2PN+1个较小原核;2.1PN)来源囊胚时进行倍性评估。
主要发现
- 注射的5026个中期II卵母细胞中,1PN占5.2%,2.1PN占0.7%。
- 异常受精卵显示胚胎发育受损(P<.01)。
- 27枚异常受精卵来源囊胚进行了倍性分析:1PN来源囊胚多数为二倍体(9/13,69.2%),少数为单倍体(3/13,23.1%),1枚为三倍体(1/13,7.7%);2.1PN来源囊胚多数为二倍体(12/14,85.7%),其余为三倍体。
- 26个PGT-A周期(26/719,3.6%)获得至少一枚异常受精卵来源囊胚;共获得8枚额外的平衡二倍体可移植胚胎;3个周期中唯一产生的平衡二倍体囊胚来自异常受精卵(3/719,0.4%)。
- 实现3例异常受精卵来源活产:1例来自1PN受精卵,2例来自2.1PN受精卵。
临床怎么用
- 在无正常受精可移植胚胎时,可移植平衡二倍体的1PN和2.1PN来源囊胚。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test whether abnormally fertilized oocyte (AFO)-derived blastocysts are diploid and can be rescued for clinical use. DESIGN: Longitudinal-cohort study from January 2015 to September 2016 involving IVF cycles with preimplantation genetic testing for aneuploidy (PGT-A). Ploidy assessment was incorporated whenever a blastocyst from a monopronuclear (1PN) or tripronuclear zygote (2PN + 1 smaller PN; 2.1 PN) was obtained. SETTING: Private IVF clinics and genetics laboratories. PATIENT(S): A total of 556 women undergoing 719 PGT-A cycles. INTERVENTION(S): Conventional chromosome analysis was performed on trophectoderm biopsies by quantitative polymerase chain reaction. For AFO-derived blastocysts, ploidy assessment was performed on the same biopsy with the use of allele ratios for hetorozygous SNPs analyzed by means of next-generation sequencing (1:1 = diploid; 2:1 = triploid; loss of heterozygosity = haploid). Balanced-diploid 1PN- and 2.1PN-derived blastocysts were transferred in the absence of normally fertilized transferable embryos. MAIN OUTCOME MEASURE(S): Ploidy constitution and clinical value of AFO-derived blastocysts in IVF PGT-A cycles. RESULT(S): Of the 5,026 metaphase II oocytes injected, 5.2% and 0.7% showed 1PN and 2.1PN, respectively. AFOs showed compromised embryo development (P<.01). Twenty-seven AFO-derived blastocysts were analyzed for ploidy constitution. The 1PN-derived blastocysts were mostly diploid (n = 9/13; 69.2%), a few were haploid (n = 3/13; 23.1%), and one was triploid (n = 1/13; 7.7%). The 2.1PN-derived blastocysts were also mostly diploid (n = 12/14; 85.7%), and the remainder were triploid. Twenty-six PGT-A cycles resulted in one or more AFO-derived blastocysts (n = 26/719; 3.6%). Overall, eight additional balanced-diploid transferable embryos were obtained from AFOs. In three cycles, the only balanced-diploid blastocyst produced was from an AFO (n = 3/719; 0.4%). Three AFO-derived live births were achieved: one from a 1PN zygote and two from 2.1PN zygotes. CONCLUSION(S): Enhanced PGT-A technologies incorporating reliable ploidy assessment provide an effective tool to rescue AFO-derived blastocysts for clinical use.
引用
- Capalbo A, Treff N, Cimadomo D, et al. Abnormally fertilized oocytes can result in healthy live births: improved genetic technologies for preimplantation genetic testing can be used to rescue viable embryos in in vitro fertilization cycles. Fertil Steril. 2017. PMID: 28923286. doi:10.1016/j.fertnstert.2017.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。